Biotechnology

AMI Pharm Advances AYP-101 to Phase 3, Paving the Way for a New Era in Fat-Reduction Injectable drugs

— Novel non-cytolytic injectable drug targets submental fat with significantly reduced pain and swelling — Phase 3 clinical trial underway in South Korea, following strong safety and efficacy results in earlier studies — AMI Pharm positions itself for global expansion in the multi-billion-dollar ...

2025-08-11 20:00 1639

Everest Medicines to Announce 2025 Interim Results on August 29, 2025

SHANGHAI, Aug. 11, 2025 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced that it will report its interim resul...

2025-08-11 17:11 1808

WuXi Biologics Launches HEK 293 Stable Cell Line Platform WuXia293 Stable for Development and Manufacturing of Difficult-to-Express Molecules

* WuXia293Stable platform demonstrates high titer, human glycosylation and improved product quality by eliminating or significantly alleviating truncation in difficult-to-express molecules. * WuXia293Stable platform maintains stable expression and consistent product quality during long-term c...

2025-08-11 16:30 1738

Akeso Announces First Patient Dosed in Phase III Trial of Ivonescimab as Consolidation Therapy for Limited-Stage SCLC After Definitive Radiotherapy

HONG KONG, Aug. 10, 2025 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in its multicenter, randomized, double-blind Phase III study (AK112-311/HARMONi-9), evaluating ivonescimab, a first-in-class PD-1/VEGF bispecific antibody deve...

2025-08-11 10:52 1392

HistoIndex Marks Another Step Forward with FibroSIGHT™ Plus: Introducing AI-based Quantitative Analysis in Fibrosis Assessment

SINGAPORE, Aug. 11, 2025 /PRNewswire/ -- HistoIndex, a pioneering leader in digital pathology solutions for chronic liver disease, has announced the launch ofFibroSIGHT™ Plus, its second Laboratory Developed Test (LDT) available in the United States. Building on the foundation of FibroSIGHT™[1], ...

2025-08-11 09:00 1500

Brain Navi Biotechnology's NaoTrac performs first surgeries in Spain

Brain Navi has officially landed in Spain! TAIPEI, Aug. 11, 2025 /PRNewswire/ -- Such an achievement has been made possible through the first of many collaborations with our valued partner, Palex Healthcare. This milestone has been reached not only thanks to Palex's solid reputation and deep exp...

2025-08-11 09:00 1371

Anbio Biotechnology Responds to Global Outbreaks with Chikungunya Rapid Test and New 15-Minute Ultra-Fast PCR System

Covering both mosquito-borne diseases and emerging respiratory pathogens, Anbio continues to advance point-of-care diagnostics for timely outbreak detection worldwide. FRANKFURT, Germany, Aug. 8, 2025 /PRNewswire/ -- In response to recent outbreaks of Chikungunya fever, Anbio Biotechnology has a...

2025-08-09 09:30 2779

GenScript Unveils New Global Identity: "Scripting Possibilities" to Power the Future of Biotechnology

PISCATAWAY, N.J., Aug. 8, 2025 /PRNewswire/ -- GenScript Biotech Corporation (HK.1548), a global leader in life sciences innovation, today unveiled its new global brand platform: Scripting Possibilities—a future-forward identity designed to match the speed, complexity, and promise of modern biote...

2025-08-08 20:30 2656

RemeGen's Independently-Developed Bispecific Antibody RC148 Approved to Proceed Phase II Clinical Trial in US by FDA

YANTAI, China, Aug. 8, 2025 /PRNewswire/ -- On August 8th, RemeGen Co., Ltd. (688331.SH/09995.HK) announces clearance of IND application by Food and Drug Administration (FDA) for phase II clinical trials for its independently-developed bispecific antibody, RC148, for the treatment of multiple ad...

2025-08-08 17:50 2344

Codex Genetics Expands Precision Oncology Portfolio with Cxbladder Genomic Urine Tests

Strategic partnership with Pacific Edge offers Hong Kong clinicians a powerful tool for non-invasive bladder cancer detection and monitoring. HONG KONG, Aug. 8, 2025 /PRNewswire/ -- Codex Genetics, one of the leading precision diagnostics companies inHong Kong, today announced an exclusive colla...

2025-08-08 17:45 2250

WuXi XDC Included in MSCI China All Share Index

SHANGHAI, Aug. 8, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate industry, today announced its inclusion in the MSCI China All Share Index, which unders...

2025-08-08 17:32 1642

WCC Biomedical@NACDS Total Store Expo: Advancing Microneedle Drug Delivery With WINMAP™ Platform

TAIPEI, Aug. 8, 2025 /PRNewswire/ -- WCC Biomedical , a leader in novel drug delivery systems, will attend the upcomingNACDS Total Store Expo (TSE), where it will spotlight its proprietary WINMAP™ microarray patch (MAP) technology and launc...

2025-08-08 09:30 1657

LabConnect Partners with Kits4Life to Reduce Kit Waste and Advance Sustainable Clinical Trials

JOHNSON CITY, Tenn., Aug. 8, 2025 /PRNewswire/ -- As part of our ongoing commitment to environmental stewardship and industry leadership in sustainable clinical research, LabConnect is proud to announce our partnership withKits4Life , an initiative of the MedSurplus Alliance. This collaboration re...

2025-08-08 00:40 1657

Minghui Pharmaceutical Announces USD 131 Million Pre-IPO Financing to Advance Late-Stage Pipeline and Global Expansion

SHANGHAI, Aug. 7, 2025 /PRNewswire/ -- Minghui Pharmaceutical ("Minghui"), a late-stage clinical biopharmaceutical company, today announced the closing of a USD 131 million Pre-IPO financing led by new investors OrbiMed and co-led by Qiming Venture Partners. Further support came from existing inve...

2025-08-07 18:00 2393

US NCI Sponsors Senhwa Biosciences' Second Program-IND Submitted for Clinical Trial Targeting MYC-Aberrant Lymphoma

TAIPEI and SAN DIEGO, Aug. 7, 2025 /PRNewswire/ -- Senhwa Biosciences, Inc. (TPEx: 6492), a new drug development company focusing on first-in-class therapeutics for oncology, rare diseases, and infectious diseases, today announced that US National Cancer Institute (NCI) sponsors Senhwa's second ...

2025-08-07 14:35 1630

XtalPi and DoveTree Announce Landmark $6 Billion AI Drug Discovery Collaboration

Strategic partnership leverages AI and robotics for novel therapeutics across oncology, immunology, inflammation, neurology, and metabolic diseases. CAMBRIDGE, Mass., Aug. 7, 2025 /PRNewswire/ -- XtalPi (2228.HK), a leading global technology company in integrating artificial intelligence (AI) and...

2025-08-07 08:05 2437

FDA approves expanded indication for AVTOZMA® (tocilizumab-anoh) intravenous (IV) formulation in cytokine release syndrome (CRS)

* Approval of AVTOZMA® (tocilizumab-anoh) intravenous infusion expands label to include treatment of adults and pediatric patients aged 2 years and older with cytokine release syndrome (CRS) [1] * AVTOMZA received FDA approval in January 2025, for multiple inflammatory indications including r...

2025-08-06 20:00 1878

The U.S. FDA Granted Fast Track Designation to Dizal's Birelentinib for Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

* Birelentinib (DZD8586) received Fast Track Designation from the U.S. FDA for relapsed/refractory CLL/SLL * Supporting data from a pooled analysis of phase I/II studies of birelentinib showed an objective response rate of 84.2% in heavily pretreated CLL/SLL patients SHANGHAI, Aug. 6, 2025 /P...

2025-08-06 19:02 1554

WuXi AppTec Named Constituent of the FTSE4Good Index Series for Third Consecutive Year

SHANGHAI, Aug. 5, 2025 /PRNewswire/ -- WuXi AppTec, a global company that provides a broad portfolio of R&D and manufacturing services to enable companies in the pharmaceutical and life science industries, today announced its inclusion in the FTSE4Good Index Series for the third consecutive year....

2025-08-06 08:00 1693

New revolutionary brain tech platform 'ScreenIT' puts smarter concussion care in reach

SYDNEY, Aug. 6, 2025 /PRNewswire/ -- A revolutionary new brain health assessment platform,ScreenIT , has officially launched, marking a major step forward in how brain function is monitored, assessed, and optimised across sport, healthcare, and rese...

2025-08-06 06:16 1620
1 ... 24252627282930 ... 340

Week's Top Stories